Morgan Stanley Maintains Overweight on Mirum Pharmaceuticals, Raises Price Target to $150

Benzinga Newsdesk www.benzinga.com Positive 79.8%

Neg 0% Neu 0% Pos 79.8%

Morgan Stanley analyst Michael Ulz maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Overweight and raises the price target from $140 to $150.